EBOS Lowers FY26 EBITDA Forecast by Up to AUD 15 Million on Elevated Fuel Prices

Fuel Price Surge Hits Healthcare Distributor's Earnings

EBOS Group Limited (ASX:EBO) has adjusted its FY26 earnings outlook downward, citing a sharp rise in fuel prices and related energy costs that have strained its logistics-heavy healthcare distribution operations. The Group now expects underlying EBITDA of approximately AUD 610–620 million, down from prior guidance of AUD 615–635 million, reflecting an additional cost burden of AUD 5–10 million absorbed to maintain uninterrupted service.

The elevated fuel prices stem from global supply disruptions and geopolitical tensions, which have also pushed up costs for hydrocarbon-derived consumables such as plastic wrapping and polystyrene foam. These factors have combined to increase direct transport and logistics expenses across EBOS’s Australian and New Zealand operations, particularly affecting its distribution-intensive businesses like Symbion.

Limited Pass-Through Capacity Amid Essential Service Obligations

Despite stable underlying demand for its products, EBOS faces constraints in passing these cost increases onto customers. The Group’s role as a critical healthcare supply chain participant, coupled with government arrangements such as the Community Service Obligation (CSO), restrict pricing flexibility. Customer affordability concerns further limit immediate cost recovery, forcing EBOS to absorb a meaningful portion of the inflationary pressure in FY26.

EBOS is engaging with the Australian Government and other stakeholders to explore fuel cost recovery mechanisms, but the timing and outcome of these discussions remain uncertain. Meanwhile, the Group has initiated efficiency and mitigation strategies expected to partly offset elevated costs in FY27, though fuel and energy price volatility continues to cloud the outlook beyond the current financial year.

Operational Continuity and Dividend Stability

The Group emphasises its commitment to maintaining consistent service delivery across its healthcare distribution network despite these headwinds. This update follows EBOS’s recent confirmation of a fully franked interim dividend with a 2% discount on its Dividend Reinvestment Plan, reflecting confidence in its underlying cash flow generation despite cost pressures.

While the trimmed EBITDA guidance signals near-term margin compression, it does not indicate a change in the Group’s long-term earnings trajectory. The additional costs are viewed as temporary and driven by external factors rather than demand deterioration. Investors may recall EBOS’s solid 13% revenue growth in the first half of FY26, which underpinned steady dividend payments and supported its operational resilience.